Enliven Therapeutics (ELVN) Current Leases (2021 - 2026)
Enliven Therapeutics (ELVN) posted Current Leases of $302000.0 for Q1 2026, down 24.31% sequentially from $399000.0 in Q4 2025, and down 17.26% YoY from $365000.0 in Q1 2025.
Enliven Therapeutics (ELVN) Current Leases (2021 - 2026) Analysis & Trends
Enliven Therapeutics has reported Current Leases for 6 years, with the latest figure at $302000.0 in Q1 2026.
- Quarterly Current Leases fell 17.26% year-over-year to $302000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $302000.0 (down 17.26% YoY) and the FY2025 annual result came in at $399000.0, changed N/A from the prior year.
- Current Leases eased to $302000.0 in Q1 2026 per ELVN's latest filing, from $399000.0 in the prior quarter.
- Over five years, Current Leases peaked at $508000.0 in Q1 2022 and troughed at $85000.0 in Q3 2024.
- A 5-year average of $329071.4 and a median of $333500.0 in 2023 frame the typical range for Current Leases.
- The sharpest annual moves came in 2024 and 2025: Current Leases plunged 74.4% in 2024, then soared 355.29% in 2025.
- Over 5 years, Current Leases stood at $323000.0 in 2022, then advanced by 3.72% to $335000.0 in 2023, then slumped by 74.63% to $85000.0 in 2024, then soared by 369.41% to $399000.0 in 2025, then fell by 24.31% to $302000.0 in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $302000.0, $399000.0, and $387000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | 597,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 597,000.00 |
| Mar 31, 2026 | 302,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 365,000.00 |
| Sep 30, 2024 | 85,000.00 |
| Jun 30, 2024 | 169,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 335,000.00 |
| Sep 30, 2023 | 332,000.00 |
| Jun 30, 2023 | 329,000.00 |
| Dec 31, 2022 | 323,000.00 |
| Jun 30, 2022 | 445,000.00 |
| Mar 31, 2022 | 508,000.00 |
| Dec 31, 2021 | 246,000.00 |
| Sep 30, 2021 | 250,000.00 |
| Jun 30, 2021 | 254,000.00 |
| Mar 31, 2021 | 257,000.00 |